Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ICCC, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
ICCC holds $7.9M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ICCC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Ejnar A. Knudsen III | 5%+ holder (13D) | 832,790 | 9.16% | 2025-11-19 |
| Michael F Brigham Director |
Insider | 205,700 | 2.26% | 2026-03-20 |
| David Scott Tomsche Director · +31,933 options |
Insider | 131,387 | 1.45% | 2025-11-25 |
| te Boekhorst Paul Francis Olivier President and CEO, Director · +317,644 options |
Insider | 34,131 | 0.38% | 2026-11-12 |
| Gloria F Basse Director · +31,933 options |
Insider | 3,530 | 0.04% | 2025-06-11 |
| Bryan K. Gathagan Director · +20,000 options |
Insider | 1,000 | 0.01% | 2025-06-12 |
Share count 9,091,361 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ICCC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →